Uncategorized

Merck’s Keytruda flunks liver cancer study

Posted on by Olivier
20
Feb

The pharma giant reported after the market closed on Tuesday that Keytruda failed the KEYNOTE-240 study for hepatocellular carcinoma, the most common type of liver cancer. The trial missed on both overall survival as well as progression-free survival. That news arrived just 3 months after the FDA offered an accelerated approval on liver cancer based on their earlier mid-stage data for the drug. 

Source: Endpoint News, February 19th (https://endpts.com/mercks-phiii-liver-cancer-study-for-keytruda-fails-on-two-key-endpoints-just-three-months-after-the-fda-gave-it-the-green-light/?utm_medium=email&utm_campaign=Wedesday%20February%2020%202019&utm_content=Wedesday%20February%2020%202019+CID_1ce1d408dbb1ba30afe90241e1a3e36f&utm_source=ENDPOINTS%20emails&utm_term=Mercks%20PhIII%20liver%20cancer%20study%20for%20Keytruda%20fails%20on%20two%20key%20endpoints%20just%20three%20months%20after%20the%20FDA%20gave%20it%20the%20green%20light)

 

[section class="login-section" visibility="hide-for-small" padding="80px"]
[/section] [section label="one" class="login-signup-section" bg="363" bg_size="original" bg_pos="50% 0%" visibility="hide-for-small"]
[/section] [section class="login-section" visibility="show-for-small"]
[/section] [section label="one" bg_color="#194295" visibility="show-for-small"]
[/section]